Related Experiment Video
Updated: Jun 10, 2025

19:57
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
18.5K
Twice-yearly lenacapavir: A milestone for HIV prevention in young African women
Silvia Nozza1, Antonella Castagna1
1Vita-Salute San Raffaele University, Milan, Italy; Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, Italy.
Med (New York, N.Y.)
|October 12, 2024
Abstract:
The PURPOSE 1 trial1 demonstrated that after 52 weeks, no cisgender women acquired HIV infection after receiving subcutaneous twice-yearly lenacapavir. HIV incidence with lenacapavir was significantly lower than HIV incidence with daily oral emtricitabine/tenofovir alafenamide (F/TAF) or daily oral emtricitabine/tenofovir disoproxil fumarate (F/TDF). It is the first pre-exposure prophylaxis regimen with 100% efficacy in young women.

